#16
|
||||
|
||||
Öèòàòà:
|
#17
|
|||
|
|||
Íà ýòîò âîïðîñ ìîæåò îòâåòèòü surgicl staging à ïîêà ýòî ãàäàíèå
íî ÿ ïîðîþñü â ëèòåðàòóðå- âîîáùå ýòî òåìà äëÿ ðàáîòû |
#18
|
||||
|
||||
Öèòàòà:
|
#19
|
||||
|
||||
Current Obstetric & Gynecologic Diagnosis & Treatment - 9th Ed. (2003)
2. Hyperplasia with atypia—Atypical hyperplasia may be simple or complex. It is characterized histologically by endometrial glands lined by enlarged cells with increased nuclear:cytoplasmic ratios. The nuclei may be irregular with coarse chromatin clumping and prominent nucleoli. These hyperplasias are generally considered premalignant. Progression to carcinoma occurs in 8% and 29% of simple atypical and complex atypical hyperplasias, respectively. Fifty to 94% of lesions regress with progestin therapy but have a higher rate of relapse when therapy is stopped compared with that of lesions without atypia. In peri- and postmenopausal patients with atypical hyperplasias who relapse after progestin therapy or who cannot tolerate its side effects, vaginal or abdominal hysterectomy is recommended. Çà ÿè÷íèêè - íè ñëîâà. Ïðåäïîëàãàåòñÿ óäàëÿòü, ó÷èò³âàÿ âîçðàñò, à åñëè 43 ãîäà?.... |
#20
|
|||
|
|||
Ýòè æå ïðîöåíòû âû íàéäåòå â íîâàêå
à âîò ðåøåíèå î ÿè÷íèêàõ - èíäèâèäóàëüíîå â 43 ãîäà êàê ÿ óæå ïèñàë ðàíåå è òðåáóåò îáñóæäåíèà âñåõ çà è ïðîòèâ ñ ñàìîé ïàöèåíêîé êñòàòè íåïëîõî âàì áûëî áû âûÿñíèòü ó íåå íàëè÷èå BRCA 1-2 and HNPCC õîòÿ è íå óâåðåí ÷òî ýòè èññëåäîâàíèÿ äåëàþòñÿ â Óêðàèíå |
#21
|
||||
|
||||
Öèòàòà:
|
#22
|
|||
|
|||
1 êîñâåííî ýòî êîíå÷íî êðóòî , îäíàêî áåç ïðîâåðêè ýòî ãàäàíèå íà êîôåéíîé ãóùå à ìåæäó òåì ðèñê ðàêà ÿè÷íèêîâ äîñòèêàåò 44 ïðîöåíòîâ â òå÷åíèè æèçíè ïî íåêîòîðûì ðàáîòàì è ïðîôèëàêòè÷åñêàÿ îâàðèýêòîìèÿ íåñîìíåííî äîëæíà îáñóæäàòüñÿ ñ òàêèìè æåíùèíàìè
2 HEREDITARY NONPOLYPOUS COLON CANCER çàáîëåâàíèå ñ íàñëåäñòâåííîé ñêëîííîñòüþ ê ðàííåìó ðàêó òîëñòîãî êèøå÷íèêà ýíäîìåòðèÿ ÿè÷íèêà ìîë æåëåçû è îïóõîëÿì íåðâíîé ñèñòåìû ñâÿçàíî ñ ìóòàöèåé ãåíà MLH1 3 Ïîõîæèé íàñëåäñòâåííûé ñèíäðîì Lynch 2- Ñâÿçàí ñìóòàöèÿìè ãåíîâ msh2 mlh1 pms1 pms2 4 È íå êàæäûé ìîæåò , à òîò êòî ÷òî çíàåò è ó÷èòñÿ â ïðîöåññå ðàáîòû è ýòî ñîâñåì íå âîïðîñ îñíàùåíèÿ |
|
#23
|
||||
|
||||
Öèòàòà:
Åùå ïî ïîâîäó BRCA 1,2 - ïîñìîòðèòå êàêîé òèï íàñëåäîâàíèÿ, ñ êàêîé ÷àñòîòîé îí ïðîÿâëÿåòñÿ ó ðîäñòâåííèêîâ. ß äóìàþ, ÷òî ïðè 44% ðàêà ÿè÷íèêîâ àíàìíåç ïîìîæåò ñäåëàòü ïðàâèëüíûé âûâîä îòíîñèòåëüíî ïðîôèëàêòè÷åñêîé îâàðèýêòîìèè. ß íå êîíñåðâàòîð è êàê òîëüêî äèàãíîòñèêóìû BRCA 1,2 ïîÿâÿòñÿ ó íàñ â ãîðîäå, ÿ áóäó â ÷èñëå ïåðâûõ, êòî èõ íàçíà÷èò P.S. Ëèðè÷åñêîå îòñòóïëåíèå - ñ BRCA è MRI êàæäûé ìîæåò |
#24
|
|||
|
|||
1 À ÿ ê àíàìíåçó îòíîøóñü î÷åíü ñåðüåçíî ïðîñòî íåîáõîäèìî ïîíÿòü ÷òî îí äîëæåí ïðîäâèãàòü íàñ â äîñòèæåíèè äèàãíîçà
òèï íàñëåäîâàíèÿ îáîèõ BRCA 1 and 2 àóòîñîìíî äîìèíàíòíûé êñòàòè íîñèòåëüñòâî ÿâëåíèå ðåäêîå îäíàêî ðèñê ðàêà ìîë æåëåçû â òå÷åíèè æèçíè åùå áîëåå âûñîêèé - äîñòèãàåò 84 ïðîöåíòîâ 2 è åùå íå äóìàéòå ÷òî çäåñü íà êàæäîì óãëó âñåì äåëàþò MRI è ïðîâåðÿþò BRCA ïðîâåðêè äîðîãèå è òðåáóþò îáîñíîâàííîñòè íàçíà÷åíèÿ |
#25
|
|||
|
|||
è íå êàæäûé ìîæåò , àòîò êòî îáëàäàåò çíàíèÿìè è ó÷èòñÿ
è ýòî íå âîïðîñ îñíàùåíèÿ |
#26
|
||||
|
||||
Öèòàòà:
|
#27
|
||||
|
||||
Öèòàòà:
Öèòàòà:
|
#28
|
|||
|
|||
Ïîäîçðåíèå íà àïïåíäèöèò - ýòî ëàïàðîòîìèÿ
â ðåäêèõ íå ÿñíûõ êëèíè÷åñêèõ ñëó÷àÿõ CT íà äåæóðñòâå |
#29
|
||||
|
||||
Öèòàòà:
À ó íàñ ÑÒ â áîëüíèöå âîîáùå íåò è ê íàì â áîëüíèöó ñâîçÿò ÷óòü ëè íå ïîëîâèíó áåðåìåííûõ ñ ïîäîçðåíèåì íà àïïåíäèöèò. Ñàìîå èíòåðåñíîå, ÷òî õèðóðãèè ó íàñ òîæå íåò À ñêîëüêî ó âàñ äåëàåòñÿ ÑÂÑ? À ó íàñ íî÷üþ äåëàþò òîëüêî "òðîå÷êó" - hb, esr, leu 2 ÷àñà, à íà ïîâòîðíûé àíàëèç íóæíî äîëãî óïðàøèâàòü ñîííîãî ëàáîðàíòà |
#30
|
||||
|
||||
A systematic review comparing endometrial ablation with hysterectomy has concluded that endometrial destruction offers an alternative to hysterectomy, that both procedures are effective, and satisfaction rates are high. However, retreatment is often necessary with ablation. [1] Level A
Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. The Cochrane Database of Systematic Reviews 1999, Issue 2 (Cochrane Review) Level A Ýòî ê âîïðîñó î àáëàöèè è ðåçåêöèè ýíäîìåòðèÿ. |